Historical Stock Chart
1 Month : From Sep 2019 to Oct 2019
By Colin Kellaher
Merck & Co. (MRK) on Friday said the U.S. Food and Drug Administration approved supplemental new-drug applications expanding the use of the HIV-1 treatments Pifeltro and Delstrigo.
The Kenilworth, N.J., drug maker said the approval expands the indications for Pifeltro, in combination with other antiretroviral agents, and Delstrigo as a complete regimen to include adults with HIV-1 infection who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to Pifeltro or the individual components of Delstrigo.
The FDA last year approved Pifeltro and Delstrigo for the treatment of HIV-1 infection in adults with no prior antiretroviral treatment history.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
September 20, 2019 07:37 ET (11:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.